Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis

Ítems similars

• Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis
  per: Xiang, Xinyu, et al.
  Publicat: (2021)
• Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis
  per: Shu, Yanyun, et al.
  Publicat: (2021)
• External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
  per: Cheung, Angela C., et al.
  Publicat: (2018)
• Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
  per: Alomari, Mohammad, et al.
  Publicat: (2019)
• Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
  per: Harms, Maren H, et al.
  Publicat: (2020)